Clinical Trial Complexity Index →

A clinical-operations planning agent polls ADW-377 monthly and uses the 5-dimension breakdown (late-phase share, large-enrollment share, industry-sponsor share, RCT share, blinded-design share) from the enriched top_drivers field to forecast CRO capacity pressure: when the index rises above 55 on a rising trend, the agent automatically flags open site-selection RFPs as operating in a high-competition environment and adjusts site fee bids upward by a configurable percentage to maintain recruitment competitiveness. The methodology_version ensures the agent's 'complexity environment' designation references the same ClinicalTrials.gov active/recruiting snapshot that underpins the score, making the bid-adjustment logic defensible to clinical leadership.

A VP of Clinical Operations at a biotech uses ADW-377 to time the launch of new Phase 2 and Phase 3 trials. When the index is near or above 55 — indicating the landscape is shifting toward more large-enrollment, industry-sponsored, late-phase trials that compete for the same investigator sites and patients — she knows site activation timelines will extend and adjusts her enrollment milestone commitments to the board accordingly. This replaces the current practice of subjectively estimating competitive pressure from lagged industry conference reports, which often arrive 3–6 months after the conditions they describe.